Advertisement

Topics

Aldeyra’s Conjunctivitis Drug in Phase III Is a Sight for Sore Eyes

20:00 EDT 25 Mar 2019 | BioSpace

Aldeyra Therapeutics, headquartered in Lexington, Mass., announced positive results from its Phase III ALLEVIATE trial of reproxalap for allergic conjunctivitis.

Original Article: Aldeyra’s Conjunctivitis Drug in Phase III Is a Sight for Sore Eyes

NEXT ARTICLE

More From BioPortfolio on "Aldeyra’s Conjunctivitis Drug in Phase III Is a Sight for Sore Eyes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...